A review argues that sepsis diagnostics are stuck less on discovering new biomarkers and more on translating candidates into certified bedside tests that fit emergency workflows. The authors organize the diagnostic landscape by regulatory status, intended use, sample type, turnaround time, and how each test supports specific antibiotic decisions under Surviving Sepsis Campaign priorities. The piece stresses that traditional soluble markers like procalcitonin, CRP, interleukin-6, and lactate often lack biological specificity, with performance confounded by surgery, trauma, renal dysfunction, and sampling timing. That regulatory-to-workflow gap is framed as the main barrier between promising biomarker papers and routine clinical adoption. For biotech diagnostic developers, the key takeaway is operational: evidence must demonstrate not only accuracy but decision impact, integration feasibility, and compliance-ready testing pathways.